Univentis Medicare

What Univentis Medicare does

Univentis Medicare Limited is an Indian pharmaceutical company incorporated in 2015 (CIN U24232MH2015PLC402722) that manufactures and distributes generic medicines across multiple dosage forms and therapeutic categories. The company is headquartered at Plot No. L6, MIDC Road, Taloja, Navi Mumbai, with a corporate office in Panchkula, Haryana, and operates through a three-division structure: Ultima (chronic and acute therapy portfolio spanning anti-diabetic, hypertension, dermatology, respiratory, gastro, antibiotics, and nutritional categories), Optima (antibiotics, analgesics, gastro, and respiratory formulations in tablet, capsule, injection, syrup, and drops forms), and Innoventis. The product portfolio spans 300+ tablet formulations, 75+ capsule/softgel products, 30+ ointments, 100+ liquid/dry syrup/drops, 30+ injections, and 50+ dermatological products.

The company's stated Quality Control System is built on four pillars — Process Ensure, Quality Delivery, Bio-Equivalence testing, and "Every Process is a Cost" — positioning bio-equivalence and cost discipline as core operational principles rather than differentiated IP. Go-to-market is a channel-partner model: Univentis distributes through a pan-India network of stockists, distributors, and retail pharmacies, with state-level field leadership referenced in internal testimonials. Products are sold at Maximum Retail Price (MRP) in Indian Rupees on a per-unit basis, with examples ranging from ₹8.68 to ₹1,067 across SKUs such as Accuzith-250, Bactofix-AZ, Fepadol-650, and Meroride 1000. The company also holds a minority stake in Sharon Bio-Medicine Limited, a Bombay Stock Exchange-listed entity with GMP-compliant API and Oral Solid dosage manufacturing capabilities and Animal Toxicology services, providing the group with backward integration exposure into intermediates and actives.

Customer focus is exclusively Indian retail pharmacies and healthcare providers — there are no disclosed enterprise customers, no international revenue, and no platform or digital-channel distribution. Revenue, headcount, and funding are not publicly disclosed; the company is privately held with no parent organization identified. Forward commercial activity is concentrated in the Optima Division, where a pipeline of upcoming products (e.g., DECACORTIL-6, FERCILIUM XT, GEMCIVENT, LAXIVENT-L, OFTIROL-OZ/OH, PANTORAZ-40/D, SPASMOVENT) has been announced, indicating continued SKU expansion within the existing India-focused generic framework.

Name

Univentis Medicare

Legal name

Univentis Medicare Limited

Website

https://univentismedicare.co.in

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Univentis Medicare Limited is a privately held Indian generic pharmaceutical company, founded in 2015, that manufactures and distributes 300+ tablets, capsules, ointments, injections, and dermatological formulations through three divisions (Ultima, Optima, Innoventis) via a pan-India network of stockists, distributors, and retail pharmacies.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic pharmaceuticals
• Medicine manufacturing
• Pharmaceutical distribution
• Affordable medicines
• Therapeutic formulations

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from manufacturing and selling pharmaceutical products including tablets, capsules, ointments, liquid preparations, and injections through distribution network

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Univentis Medicare Limited manufactures and distributes affordable generic pharmaceutical formulations across India through three divisions (Ultima, Optima, Innoventis). The company produces a diverse portfolio including 300+ tablet formulations, 75+ capsules/softgels, 30+ ointments, 100+ liquid/dry syrups/drops, 30+ injections, and 50+ dermatological products spanning therapeutic categories such as anti-diabetic, hypertension, dermatology, respiratory, multivitamins, analgesics, gastro-intestinal, and antibiotics. Products reach end users via a pan-India network of stockists, distributors, and retail pharmacies.

Product overview

Univentis Medicare Limited is an Indian pharmaceutical company with three main divisions: Ultima, Optima, and Innoventis. The company manufactures and markets over 300+ tablet formulations, 75+ capsule/softgel products, 30+ ointments, 100+ liquid/dry syrup/drops, 30+ injections, and 50+ differential products across therapeutic categories including anti-diabetic, hypertension, derma, anti-cold/allergies, multivitamins, analgesics, gastro-intestinal, antibiotics, and respiratory treatments. The company operates through subsidiaries including Sharon Bio-Medicine Limited (listed on Bombay Stock Exchange), providing integrated pharmaceutical services from intermediates to finished dosages.

Differentiator

Problem solved

Functional benefit

Brands

• Ultima Division: Product division focusing on Anti Diabetic, Hypertension, Derma, Anti Cold, Allergies, Anti Asthmatic, Bronchodilator, Multivitamin, B-Complex, Iron Supplement, Calcium, Analgesic, Antipyretic, Anti Inflammatory, Gastro, Antidiarrheal, Antispasmodic, Antibiotic, and Miscellaneous products
• Optima Division
• Innoventis

Products and services

• Ultima Division Product Portfolio
• Optima Division Product Portfolio
• Innoventis Medicare Product Division
• AdiGard Heel Care Cream

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Sharon Bio-Medicine LimitedcoreStrategic or Co-development PartnerSubsidiary company listed at Bombay Stock Exchange, providing pharmaceutical products and services including Animal Toxicology and Manufacturing of Finished Dosages. Sharon Bio-Medicine Limited has capabilities in development and manufacturing of Pharmaceutical Intermediates and Actives, with GMP compliant API and Oral Solid dosage manufacturing facilities.

Scale indicators8 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• JB Chemicals & Pharmaceuticals: Mid-sized Indian pharma with a focus on formulations in gastro, anti-infectives, and vitamins—overlapping therapeutic areas with Univentis and similar domestic distribution model.
• Mankind Pharma: Indian generics leader with pan-India distribution, broad therapeutic portfolio, and a strong focus on affordability—Univentis's value positioning and channel model closely mirror Mankind's playbook.
• Eris Lifesciences: Indian pharma company with a chronic-disease focused generics portfolio (diabetes, cardiology, dermatology) and a strong field-force distribution model—comparable therapeutic mix and GTM motion to Univentis.
• FDC Limited: Mid-sized Indian generic pharma focused on formulations across anti-infectives, gastro, and vitamins, with a domestic distribution-led model very similar to Univentis's positioning.
• Alkem Laboratories: Indian generic pharmaceutical manufacturer with broad therapeutic portfolio across anti-infectives, gastro, vitamins, and dermatology—directly comparable to Univentis's multi-category generics approach with pan-India distribution.

Broad incumbents

• Glenmark Pharmaceuticals: Indian-headquartered pharma with significant domestic generics presence in dermatology, respiratory, and anti-infectives—overlapping therapeutic footprint with Univentis.
• Cipla Limited: Major Indian pharmaceutical company with extensive domestic distribution and broad therapeutic coverage—relevant comparable given Univentis's generic retail focus.
• Torrent Pharmaceuticals: Established Indian generic pharma with broader portfolio and international presence; comparable in therapeutic categories covered and pan-India distribution depth.
• Ajanta Pharma: Indian specialty generics manufacturer with strong domestic field force and broad therapeutic categories (anti-infectives, cardiology, dermatology)—comparable business model and distribution depth.

Emerging players

• Sharon Bio-Medicine Limited: Bombay Stock Exchange-listed pharma manufacturer of APIs, intermediates, and finished dosages—in which Univentis holds a minority stake—directly comparable as a sister strategic asset and operational peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/univentis525
• Facebookfacebook.com/Univentis
• LinkedInlinkedin.com/company/univentis-medicare-ltd

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Univentis Medicare